Skip to main content
Caplight Logo









Tacit Therapeutics

Tacit Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://tacittx.com/

Last Round

Series A

Mar 9, 2026

Total Funding Raised

$29.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Tacit Therapeutics is a biotechnology company that develops RNA-targeted treatments to repair mutated genes using its proprietary Splicing-Directed Repair™ technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

RNA therapeuticsRNA trans-splicinggenetic medicineneurological diseasedrug discoverybiotechprecision medicineRNA editinggene therapysynthetic biologyAI drug discoverypre-clinical researchbiotech platformtherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tacit Therapeutics Comparables

Compare Tacit Therapeutics with similar companies based on industry and business-model similarity.

Tacit Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ascidian Therapeutics
88%
Amber Bio
84%
Transit Therapeutics, Inc.
84%

Tacit Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 9, 2026
GrantJan 15, 2024
Series AJun 8, 2022

Key People

Founding team and executive leadership

David Nelles

CEO, Founder

Founding Team

Tacit Therapeutics Investors

Notable investors and investment history

Tacit Therapeutics investors
InvestorRounds
Mitsui Global InvestmentSeries A
Eisai InnovationSeries A
Michigan Capital NetworkSeries A
Civilization VenturesSeries A
KdT VenturesSeries A
National Science FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 13, 2026

    Monthly visitors increased 49% MoM, reaching 2.6K.

Tacit Therapeutics Filings

Explore SEC and related filing metadata, where available.

Tacit Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Tacit Therapeutics's valuation, stock price, and market status.

Is Tacit Therapeutics a public or private company?

Tacit Therapeutics is a private company.

What is the current stock price of Tacit Therapeutics?

Tacit Therapeutics is a private company, so its shares have no public market price. Caplight tracks Tacit Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Tacit Therapeutics worth (valuation)?

Valuation information for Tacit Therapeutics is not publicly available.

Can I buy Tacit Therapeutics stock?

Tacit Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Tacit Therapeutics's last funding round?

Tacit Therapeutics's most recent funding round was Series A on March 9, 2026.

Who are the main investors in Tacit Therapeutics?

Key investors in Tacit Therapeutics include National Science Foundation.

Will Tacit Therapeutics IPO soon?

No public IPO plans have been announced for Tacit Therapeutics.

How can I track Tacit Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades in Tacit Therapeutics's shares on secondary markets.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range13
Year Founded2021
Last FundingMar 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?